基于5-氨基吡唑-4-甲酰胺的化合物可抑制微小隐孢子虫的生长。
5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
作者信息
Huang Wenlin, Choi Ryan, Hulverson Matthew A, Zhang Zhongsheng, McCloskey Molly C, Schaefer Deborah A, Whitman Grant R, Barrett Lynn K, Vidadala Rama Subba Rao, Riggs Michael W, Maly Dustin J, Van Voorhis Wesley C, Ojo Kayode K, Fan Erkang
机构信息
Department of Biochemistry, University of Washington, Seattle, Washington, USA.
Division of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
出版信息
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00020-17. Print 2017 Aug.
Abstract
calcium-dependent protein kinase 1 (CDPK1) is a promising target for drug development against cryptosporidiosis. We report a series of low-nanomolar CDPK1 5-aminopyrazole-4-carboxamide (AC) scaffold inhibitors that also potently inhibit growth Correlation between anti-CDPK1 and growth inhibition, as previously reported for pyrazolopyrimidines, was not apparent. Nonetheless, lead AC compounds exhibited a substantial reduction of parasite burden in the neonatal mouse cryptosporidiosis model when dosed at 25 mg/kg.
摘要
钙依赖性蛋白激酶1（CDPK1）是抗隐孢子虫病药物开发的一个有前景的靶点。我们报告了一系列低纳摩尔浓度的CDPK1 5-氨基吡唑-4-甲酰胺（AC）支架抑制剂，它们也能有效抑制生长。与之前报道的吡唑并嘧啶不同，抗CDPK1作用与生长抑制之间的相关性并不明显。尽管如此，先导AC化合物在新生小鼠隐孢子虫病模型中以25 mg/kg给药时，寄生虫负荷显著降低。
相似文献
1
5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00020-17. Print 2017 Aug.
2
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.
J Infect Dis. 2013 Oct 15;208(8):1342-8. doi: 10.1093/infdis/jit327. Epub 2013 Jul 21.
3
Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
Antimicrob Agents Chemother. 2015 Nov 9;60(1):570-9. doi: 10.1128/AAC.01915-15. Print 2016 Jan.
4
Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
J Med Chem. 2019 Mar 28;62(6):3135-3146. doi: 10.1021/acs.jmedchem.9b00069. Epub 2019 Mar 15.
5
Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
J Infect Dis. 2017 Apr 15;215(8):1275-1284. doi: 10.1093/infdis/jix120.
6
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
Antimicrob Agents Chemother. 2008 Mar;52(3):1150-2. doi: 10.1128/AAC.01019-07. Epub 2007 Dec 26.
7
A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
Antimicrob Agents Chemother. 2013 Dec;57(12):6063-73. doi: 10.1128/AAC.00734-13. Epub 2013 Sep 23.
8
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0142522. doi: 10.1128/aac.01425-22. Epub 2023 Mar 15.
9
7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.
ACS Infect Dis. 2018 Apr 13;4(4):516-522. doi: 10.1021/acsinfecdis.7b00224. Epub 2018 Mar 16.
10
Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
PLoS Pathog. 2019 Jul 29;15(7):e1007953. doi: 10.1371/journal.ppat.1007953. eCollection 2019 Jul.
引用本文的文献
1
Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice.
Nat Commun. 2024 Sep 27;15(1):8272. doi: 10.1038/s41467-024-52658-y.
2
Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition.
Bioorg Med Chem Lett. 2023 Jun 15;90:129328. doi: 10.1016/j.bmcl.2023.129328. Epub 2023 May 15.
3
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0142522. doi: 10.1128/aac.01425-22. Epub 2023 Mar 15.
4
An update on biology and therapeutic avenues.
J Parasit Dis. 2022 Sep;46(3):923-939. doi: 10.1007/s12639-022-01510-5. Epub 2022 Jun 22.
5
Comparative Characterization of CpCDPK1 and CpCDPK9, Two Potential Drug Targets Against Cryptosporidiosis.
Microorganisms. 2022 Feb 1;10(2):333. doi: 10.3390/microorganisms10020333.
6
Spontaneous Selection of Drug Resistance in a Calf Model of Infection.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00023-21.
7
Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis.
ACS Infect Dis. 2021 May 14;7(5):1200-1207. doi: 10.1021/acsinfecdis.0c00803. Epub 2021 Feb 10.
8
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.
Vet Parasitol. 2021 Jan;289:109336. doi: 10.1016/j.vetpar.2020.109336. Epub 2020 Dec 15.
9
Characterization of Calcium-Dependent Protein Kinases 3, a Protein Involved in Growth of .
Front Microbiol. 2020 May 8;11:907. doi: 10.3389/fmicb.2020.00907. eCollection 2020.
10
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned.
Int J Parasitol. 2020 May;50(5):413-422. doi: 10.1016/j.ijpara.2020.01.006. Epub 2020 Mar 26.
本文引用的文献
1
Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
J Infect Dis. 2017 Apr 15;215(8):1275-1284. doi: 10.1093/infdis/jix120.
2
Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.
J Infect Dis. 2016 Dec 15;214(12):1856-1864. doi: 10.1093/infdis/jiw488. Epub 2016 Oct 17.
3
5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents.
Bioorg Med Chem Lett. 2016 Nov 15;26(22):5487-5491. doi: 10.1016/j.bmcl.2016.10.014. Epub 2016 Oct 10.
4
A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice.
J Infect Dis. 2016 Dec 15;214(12):1850-1855. doi: 10.1093/infdis/jiw481. Epub 2016 Oct 12.
5
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of CDPK1.
ACS Med Chem Lett. 2015 Oct 22;6(12):1184-1189. doi: 10.1021/acsmedchemlett.5b00319. eCollection 2015 Dec 10.
6
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.
Lancet Infect Dis. 2015 Jan;15(1):85-94. doi: 10.1016/S1473-3099(14)70772-8. Epub 2014 Sep 29.
7
Potent and selective inhibitors of CDPK1 from and based on a 5-aminopyrazole-4-carboxamide scaffold.
ACS Med Chem Lett. 2014 Jan 9;5(1):40-44. doi: 10.1021/ml400315s.
8
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.
J Infect Dis. 2013 Oct 15;208(8):1342-8. doi: 10.1093/infdis/jit327. Epub 2013 Jul 21.
9
Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.
Lancet. 2013 Jul 20;382(9888):209-22. doi: 10.1016/S0140-6736(13)60844-2. Epub 2013 May 14.
10
Burden of disease from cryptosporidiosis.
Curr Opin Infect Dis. 2012 Oct;25(5):555-63. doi: 10.1097/QCO.0b013e328357e569.
Zotero 插件